IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 1 CLINICAL STUDY PROTOCOL  
 
A Phase 2 Multicenter, Double -blind, Randomized, Placebo -Controlled Trial 
to Evaluate  Oral Ifetroban in Subjects with Symptomatic Aspi[INVESTIGATOR_767904] (AERD)  
 
Number:  CPI-IFE-006 
 
 
Protocol Version  
 
Version Number:  Original Protocol  
Final:    22 December  2016 
 
Amendment:    01 
Revised Final:  [ADDRESS_1053033] be informed that the information is 
privileged or confidential and may not be further disclosed by [CONTACT_476]. These restrictions on disclosure will 
apply equally to all future information supplied to you which is indicated as privileged o r confidential.  
 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 2 RESPONSIBLE PERSONNEL   
Sponsor - Medically Responsible Person   [CONTACT_2728]’s Coordinating Office  
   
   
   
   
   
   
   
   
   
   
   
   
Sponsor’s Clinical Operations    Coordinating Investigator  
   
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
 
[CONTACT_116909] 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 3 1 INVESTIGATOR’S STATEMENT  
I have read and agree to the Protocol CPI-IFE-006, “ A Phase 2 Multicenter, Double -blind, 
Randomized, Placebo -Controlled Trial to Evaluate  Oral Ifetroban in Subjects with Symptomatic 
Aspi[INVESTIGATOR_767905] (AERD) , Amendment 01  dated 02 May 2018.”  I am 
aware of my responsibilities as an Investigator under the guidelines of Good Clinical Practice 
(GCP), local regulations (as applicable) and the study protocol.  I agree to conduct the study 
according to these guidelines and to appropriately direct a nd assist the staff under my control, who 
will be invol ved in the study.  
 
 
 
Principal Investigator  
[INVESTIGATOR_7496]:     
   Date of Signature  
 
  
  
 
[CONTACT_767969]:     
   Date of [INVESTIGATOR_7496]  
  
  
  
[INVESTIGATOR_7496]:     
   Date of Signature  
  
[CONTACT_116909] 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 4 2 SYNOPSIS  
Name [CONTACT_790]:  
Cumberland Pharmaceuticals  Name [CONTACT_2756]:  
Ifetroban Capsules  Name [CONTACT_3261]:  
ifetroban  
Title of Study:  
A Phase 2 Multicenter, Double -blind, Randomized, Placebo -Controlled Trial to Evaluate  Oral 
Ifetroban in Subjects with Symptomatic Aspi[INVESTIGATOR_767905] (AERD)  
Study Centers (Planned):  Eight  Phase of Development:  II 
Expected Study Duration (per subject ): Screening period ( 3 weeks) + Treatment period (8 
weeks) + Post-treatment  period (2 weeks) = 1 3 weeks  
Objectives:  
Primary Study Objective  
• Determine the efficacy of ifetroban compared to placebo to improve sino-nasal symptoms 
and quality of life  (QoL) using the Sino-nasal Outcome  Test ( SNOT ) - [ADDRESS_1053034] s. 
Secondary Study Objectives  
• Evaluate  the effect  of ifetroban on asthma symptoms by [CONTACT_51834][INVESTIGATOR_12194] 1 (FEV1) 
compared to baseline.  
• Assess nasal symptoms and QoL using the peak Nasal Inspi[INVESTIGATOR_29330] ( PNIFR) , 
University of Pennsylvania Smell Identification Test (UPSIT), fractional exhaled nitric oxide 
(FeNO), Asthma Control Questionnaire (ACQ) - 7 and Total Nasal Symptom Score (TNSS)  
• Determine whether ifetroban reduces the frequency and severity of asthma exacerbations and 
chronic sinusitis as well as the frequency of rescue medication and antibiotic use.  
• Evaluate the pharmacodynamic  effects of TPr blockade on eicosanoids and eosinophil count  
Methodology:  This is a multicenter , randomized, double -blind , placebo -controlled  study  to 
evaluate  the effect  of 200 mg of oral ifetroban administered once daily for eight  weeks.  
Number of subjects (planned):   A total of [ADDRESS_1053035] s will be randomized: 38 ifetroban, 
38 placebo  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 5 Name [CONTACT_790]:  
Cumberland Pharmaceuticals  Name [CONTACT_2756]:  
Ifetroban Capsules  Name [CONTACT_3261]:  
ifetroban  
Study Population – Main Selection Criteria  
Inclusion  criteria : 
1. History of physician -diagnosed asthma  
2. History of nasal polyposis  
3. History of at least two reactions to oral aspi[INVESTIGATOR_767906] (cough, chest tightness, wheezing, 
dyspnea)  or one reaction that was life -threatening and required hospi[INVESTIGATOR_059] , or a 
diagnosis of AERD by a physician -conducted challenge to aspi[INVESTIGATOR_767907].  
4. Stable asthma (post -bronchodilator FEV1 of ≥  60%, no glucocorticoid burst for at least 
two weeks prior to starting treatment, no hospi[INVESTIGATOR_767908]  a dose >1000 µg 
fluticasone or equivalent  daily ). 
5. ≥ [ADDRESS_1053036] (SNOT) – 22. 
Exclusion criteria:  
1. Current smoking, defined as daily tobacco smoking in the last six months and at least one 
instance of tobacco smoking in the last three  months.  
2. Current pregnancy or breastfeeding  
3. Use of oral or systemic steroids  (e.g. prednisone or equivalent)  > [ADDRESS_1053037] two weeks  before starting treatment.  
5. Less than 12 months of allergy shots (maintenance dose of allergy shots are allowed if 
treatment  duration exceeds 12 months).   
6. Any use of nonsteroidal anti -inflammatory drugs (NSAIDs) or any drug that inhibits the 
cyclooxygenase enzyme in the last two weeks before starting treatment.  
7. History of bleeding diathesis or use of anticoagulant or antiplatelet drugs in the last two 
weeks  before starting treatment.  
8. Any immunosuppressive  treatment including but not limited to methotrexate, 
cyclosporine, mycophenolate, tacrolimus , gold, penicillamine, sulfasalazine, 
hydroxychloroquine, azathioprine and cyclophosphamide in the last two weeks before 
starting treatment  (maintenance dose of allergy shots are allowed if treatment duration 
exceeds 12 months) . Biologics/immunotherapi[INVESTIGATOR_767909].  
9. Endoscopic sinus surgery / polypectomy within the past three  months  
10. Previously treated in a clinical trial with ifetroban  within the past three  months . 
11. Previously treated with other investigational drugs within eight  weeks or five half-lives, 
whichever is longer, before screening  
12. Conditions/concomitant disease which make them unevaluable for the efficacy endpoints  
Investigational Medicinal Product (IMP) , dose and mode of administration:  
Oral ifetroban  capsules  (200 mg )  
Duration of treatment: eight  weeks  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 6 Name [CONTACT_790]:  
Cumberland Pharmaceuticals  Name [CONTACT_2756]:  
Ifetroban Capsules  Name [CONTACT_3261]:  
ifetroban  
Reference therapy, dose and mode of administration:  
Matching oral placebo capsules  
Endpoints:  
Efficacy:  SNOT -22, ACQ -7, FEV 1, UPSIT,  FeNO, PNIFR and TNSS   
Safety, tolerability and other exploratory endpoints:  vital signs, adverse events (AE), physical 
examination, clinical laboratory tests and biomarkers.  
Sample Size : 
38 subjects per group will provide 90% power for  the comparison of ifetroban and placebo with 
respect  to the change from baseline in SNOT -22 scores at Week  8 (two-sided, level 0.05), 
assuming  a common standard deviation of 16  and a true difference is 12. 
Randomization:  
Subject s will be randomized using a 1:1 randomization ratio for ifetroban 2 00 mg daily  for eight  
weeks, or placebo daily  for eight  weeks.  
 
Analysis Population:  
All subjects who received at least one dose of study medication will be included in the Safety 
Population. All safety data, including AEs, laboratory parameter, vital signs, FEV1 and physical 
examinations, will be summarized for subjects in the Safety Population.  
 
The Intent -To-Treat (ITT) Population will consist of all treated subjects with at least one post -
baseline assessment of SNOT -22. The Per Protocol (PP) Population  will consist of all subjects in  
the ITT population with no major protocol violations , including violation of inclusion or 
exclusion criteria or insufficient dosing.  All e fficacy  analyses will be performed  for both the ITT 
and PP Population s. Summary statistics will be presented for each corresponding analysis . 
 
Primary Analysis:  
The primary efficacy endpoint is the Change From Baseline ( CFB ) in SNOT -22 score and the 
primary analysis is the analysis of CFB in SNOT -22 at Week 8, using Analysis of Covariance 
(ANCOV A), with SNOT -22 at Baseline included as the only covariate.  
 
Secondary Analys es 
CFB in ACQ -7 and CFB in TNSS at Week 8 will be analyzed using ANCOV A, with the 
corresponding value at Baseline included as the only covariate. These variables, as well as CFB 
in SNOT -22, at Week 4 will also be analyzed as ancillary analyses.  
  
Analyses of CFB for other continuous efficacy variables at Weeks 4 and 8 will be performed as 
ancillary analyses  using ANCOV A with the corresponding value at Baseline included as the only 
covariate.  Responder analyses, defined as a ny improvement in SNOT -22, ACQ -7, and TNSS (Yes 
or No) at Weeks 4 and 8 will be performed  as ancillary analyses using the normal approximation 
to the binomial distribution, assuming unequal variances.   
 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 7 3 TABLE OF CONTENTS  
1 INVESTIGATOR’S STATEMENT  ................................ ................................ .............  [ADDRESS_1053038] OF ABBREVIATIONS  ................................ ................................ ....................  10 
5 INTRODUCTION  ................................ ................................ ................................ ..... 12 
5.1 Background Information  ................................ ................................ .......................  12 
5.2 Stage of Development  ................................ ................................ ...........................  14 
5.3 Trial Rationale  ................................ ................................ ................................ ....... 14 
5.4 Dose Rationale  ................................ ................................ ................................ ....... 14 
5.5 Risk-Benefit Assessment  ................................ ................................ .......................  15 
6 STUDY OBJECTIVES & ENDPOINTS  ................................ ................................ .. 15 
6.1 Primary Objective  ................................ ................................ ................................ .. 15 
6.2 Secondary Objectives  ................................ ................................ ............................  15 
6.3 Primary Efficacy Endpoint  ................................ ................................ ....................  16 
6.4 Secondary Efficacy Endpoints and Other Exploratory Endpoints  ........................  16 
6.4.1  Second and Exploratory Efficacy Endpoints  ................................ .....................  16 
6.4.2  Safety Endpoints  ................................ ................................ ................................  16 
7 STUDY DESCRIPTION  ................................ ................................ ...........................  17 
7.1 Study Design  ................................ ................................ ................................ .........  17 
7.2 Randomization and Blinding Conditions and Methods  ................................ .........  18 
7.3 Drugs and Dosages  ................................ ................................ ................................  18 
7.4 Selection of Study Population  ................................ ................................ ...............  19 
7.4.1  Inclusion Criteria  ................................ ................................ ...............................  19 
7.4.2  Exclusion Criteria  ................................ ................................ ..............................  20 
7.5 Concomitant Medications  ................................ ................................ ......................  20 
7.6 Prohibited Medications or Procedures  ................................ ................................ ... 22 
7.7 Dietary Requirements  ................................ ................................ ............................  22 
8 STUDY VISITS AND PROCEDURES  ................................ ................................ .... 23 
8.1 Overview – Schedule of Time and Events  ................................ ............................  23 
8.1.1  Screening Period  ................................ ................................ ................................  23 
8.1.2  Treatment Period  ................................ ................................ ...............................  25 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053039] Populations for Analysis  ................................ ................................ ...........  37 
11.2.1  Safety Population  ................................ ................................ ...............................  37 
11.2.2  Intent -to-Treat Population  ................................ ................................ .................  37 
11.2.3  Per Protocol Population  ................................ ................................ .....................  37 
11.3  Subgroup analysis  ................................ ................................ ................................ .. 37 
11.4  Randomization  ................................ ................................ ................................ ....... 38 
11.5  Methods for Handling Missing Data  ................................ ................................ ..... 38 
11.6  Data Analysis Plan  ................................ ................................ ................................ . 38 
11.6.1  Demographic and Baseline Parameters  ................................ .............................  38 
11.6.2  Exposure and Compliance  ................................ ................................ .................  38 
11.6.3  Efficacy Analyses  ................................ ................................ ..............................  38 
[IP_ADDRESS]  Primary Analysis  ................................ ................................ ............................  39 
[IP_ADDRESS]  Analysis of secondary endpoints  ................................ ................................ ... 39 
11.6.4  Safety Parameters  ................................ ................................ ..............................  39 
12 STUDY MANAGEMENT AND DATA COLLECTION  ................................ ..........  40 
12.1  Confidentiality  ................................ ................................ ................................ ....... 40 
12.2  Source Documents  ................................ ................................ ................................ . 40 
12.3  Case Report Forms  ................................ ................................ ................................  40 
12.4  Records Retention  ................................ ................................ ................................ . 41 
13 STUDY MONITORING, AUDITING, AND INSPECTING  ................................ ... 41 
13.1  Study Monitoring Plan  ................................ ................................ ..........................  41 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 9 14 ETHICAL CONSIDERATIONS  ................................ ................................ ...............  41 
14.1  Informed Consent  ................................ ................................ ................................ .. 41 
14.2  Protocol Compliance  ................................ ................................ .............................  42 
14.3  Study Files  ................................ ................................ ................................ .............  42 
15 REFERENCES  ................................ ................................ ................................ ..........  43 
16 APPENDICES  ................................ ................................ ................................ ...........  45 
16.1  Protection of Human Subjects  ................................ ................................ ...............  45 
16.1.1  Basic Elements Of Informed Consent  ................................ ...............................  45 
16.2  Requisite Documents for Approval of Study Site  ................................ .................  47 
16.3  Responsibilities and Obligations of Investigators and Sponsors  ...........................  48 
16.3.1  Sponsor/Study Monitor  ................................ ................................ .....................  [ADDRESS_1053040] (SNOT -22)................................ .......................  51 
16.5  PNIFR Methodology  ................................ ................................ .............................  53 
16.6  Total Nasal Symptom Score (TNSS)  ................................ ................................ ..... 54 
16.7  Asthma Control Questionnaire – 7 (ACQ -7) ................................ .........................  55 
16.8  Adult Equipotent Daily Doses of Inhaled Glucocorticosteroids  ...........................  57 
16.9  Self-assessment of Treatment (Optional)  ................................ ..............................  58 
  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053041] OF ABBREVIATIONS  
Abbreviation  Definition  
5-LO 
ACQ  5-Lipoxygenase  
Asthma Control Questionnaire  
AE Adverse Event/Experience  
AERD  Aspi[INVESTIGATOR_767910] A  Analysis of Covariance  
AUC  Area Under the Curve  
C Celsius  
CFB  Change From Baseline  
CFR  Code of Federal Regulations  
cm Centimeter  
Cmax Maximum Plasma Concentration  
COX  Cyclooxygenase  
CRF  Case Report Form  
CPI [INVESTIGATOR_507600].  
cysLT  Cysteinyl Leukotriene  
CysLT1R  Cysteinyl Leukotriene [ADDRESS_1053042] ; synonymous with “study drug”  
INR International normalized ratio  
IRB 
ITT 
kg 
L Institutional Review Board  
Intent -To-Treat  
Kilogram  
Liter  
LTC 4 Leukotriene C 4 
LTE 4 Leukotriene E 4 
MCID  Minimal Clinically Important Difference  
MedDRA  Medical Dictionary for Regulatory Activities  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 11 Abbreviation  Definition  
mg Milligram  
mL Milliliter  
NSAID  Nonsteroidal Anti -inflammatory Drug  
PD Pharmacodynamic  
PG Prostaglandin  
PGD 2 Prostaglandin D 2 
PNIF R 
PP 
PRN  Peak Nasal Inspi[INVESTIGATOR_767911]  (use when necessary ) 
PT Prothrombin time  
Ptges  PGE2 synthase  
QoL Quality of Life  
SAE  Serious Adverse Event/Experience  
SNOT -[ADDRESS_1053043]  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 12 5 INTRODUCTION  
This study is to be performed in accordance with the International Conference on Harmonization ’s 
(ICH)  E6 guideline for Good Clinical Practice (GCP), the ethical principles that have their origin 
in the Declaration of Helsinki, Title 21 of the Code of Federal Regulations (CFR) Parts 50, 56 and 
312. 
5.1 Background Information  
Ifetroban is a new chemical entity under development  by [INVESTIGATOR_507600]. (CPI) 
for aspi[INVESTIGATOR_437708] ( AERD ) and other disease s. The current formulation of 
oral ifetroban is a [ADDRESS_1053044] of 
the thromboxane prostanoid receptor  (TPr) , and has been studied previously in healthy volunteers 
and subject s with cardiovascular diseases . A large safety database exists from this work.  CPI [INVESTIGATOR_767912] s with he patorenal syndrome  
and portal hypertension , and the oral fo rmulation in systemic sclerosis.  
AERD affects 7 -10% of all asthmatics and ~15% of severe asthmatics ( Rajan 2015 ). AERD is 
characterized clinically by [CONTACT_4221], severe rhinosinusitis with nasal polyposis, tissue eosinophilia, 
and characteristic respi[INVESTIGATOR_767913] -1 (COX -1) (White 2012 ). Biochemically, AERD is marked by [CONTACT_46431] -activity of the 
5-lipoxygenase (5 -LO) pathway and high levels o f leukotriene E4 (LTE 4), the stable end -product 
of cysteinyl leukotriene (cys LT) metabolism  (Laidlaw 2012 ). There is no known cure for AERD, 
but ch ronic high-dose aspi[INVESTIGATOR_767914], decrease in nasal polyp formation, decrease in sinus 
infections/sinus surgery, improvement in asthma outcomes, and decreased need for nasal or 
systemic corticosteroids  (Berges -Gimeno 2003 ). High-dose aspi[INVESTIGATOR_767915]  (Nasser 1995 ), although it has been shown to  reduce end -organ reactivity 
to LTE4 ( Arm 1989 ) and nasal mucosal expression of CysLT1R ( Sousa 2002 ). Moreover , 30% of 
subjects find no benefit from high -dose aspi[INVESTIGATOR_259949] ( Berges -Gimeno 2003 ).  
Preclinical studies revealed that a murine model of AERD generated by [CONTACT_767942]2 synthase (Ptges -/- mice) display bronchoconstriction, intrapulmonary platelet and 
mast cell  activation, and release prostaglandin D 2 (PGD2 ) and cysLTs from the ir lungs in response 
to aspi[INVESTIGATOR_437782] ( Liu 2013 ). These processes are dramatically attenuated  by [CONTACT_69506] -term 
blockade of TP r, or by [CONTACT_767943]. Moreover, longer -term TP r blockade in this model 
significantly suppresses eosinophilic inflammation by [CONTACT_767944] -driven leukocyte 
adhesion ( Liu 2012 ) and lung IL -33 expression. Oral administration of ifetroban is capable of both 
preempting and reversing TPr -induced bronchospasm in rat and guinea pig studies ( Schumacher 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 13 1990a ; Schumacher 1990b ). These  studies suggest that TPr signaling is essential  both upstream 
and downstream of the cysLTs, and is involved at multipl e steps in AERD pathophysiology.  TPr, 
its ligands  and cysLTs are critical to a feed-forward network of mediators and cells that perpetuate  
respi[INVESTIGATOR_28345], tissue remodeling, end -organ dysfunction, and clinical reactions to 
COX -[ADDRESS_1053045]  (Figure 5.1). 
Figure 5.[ADDRESS_1053046]  = Aspi[INVESTIGATOR_767905];  CysLT  = cysteinyl leukotriene 1 receptor;  Eos = eosinophil;  LTC 4 
= leukotriene C 4; MC = mast cell ; PGD 2 = prostaglandin D 2; PMN  = polymorphonuclear leukocytes;  TPr = 
thromboxane prostanoid receptor;  TXA 2 = thromboxane A [ADDRESS_1053047] prior to and during an aspi[INVESTIGATOR_437782], there were  several 
noteworthy  trend s in favor of the ifetroban group: greater improvements to PNIFR and TNSS, half 
of all initial aspi[INVESTIGATOR_248] -provoked reactions occurred at a higher dose of aspi[INVESTIGATOR_248], and fewer  rescue 
medication s were  required in response to the aspi[INVESTIGATOR_248] -provoked reaction.  The safety results 
demonstrated ifetroban did not cause a respi[INVESTIGATOR_767916] . There were no treatment -related adverse events 
reported in the ifetroban group  prior to the aspi[INVESTIGATOR_437782] . Collectively, these observations in 
both mice and humans suggest the TPr plays a major role in AERD and that blockade of this 
pathway may improve baseline disease control in AERD and blunt the feed -forward loop that 
drives the disease.  

IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053048] -like Ptges -
/- mice  including preventing cysLT and PGD2 generation. PGD 2, along with the classical TPr 
agonist,  thromboxane A 2 (TXA 2), may be acting in concert to cause bronchoconstriction and sino -
nasal symptoms in AERD  subject s. Clinical studies identified  subject s with AERD as having  
elevated levels of TPr -active metabolites in their urine ( Bochenek  2003 ) and these levels increase 
further during an aspi[INVESTIGATOR_767917] a decrease in FEV1 and TNSS ( Cahill 
2015 ). Further, expression of both thromboxane A 2 synthase (TBXAS) and TPr are markedly 
elevated in nasal polyps from subjects with AERD  thus potentially driving the effects of TXA2 
and TPr within the feed-forward loop (unpublished).  
Ifetroban is under development as a potential novel treatment for AERD. CPI-IFE-[ADDRESS_1053049] s.  
5.4 Dose Rationale  
Oral ifetroban doses ≥ [ADDRESS_1053050] been shown to inhibit TP r induced platelet aggregation, with 
corresponding plasma C max levels of > 500 ng/mL. The bioavailability of oral ifetroban  capsules 
has previously been found to be ≈ 42%. Our recent safety study in subject s with a history of AERD 
found oral ifetroban at [ADDRESS_1053051].  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053052] did not demonstrate any abnormal laboratory findings or 
bleeding events , clinical laboratory results will be monitored for possible abnormalities related to 
clotting or bleeding  in all study subjects .  
Given the preclinical and clinical data, there is a  potential benefit to  study  subjects randomized  to 
the ifetroban  arm to experience a reduction in the incidence and severity of respi[INVESTIGATOR_560088] . 
If TPr antagonism does indeed provide  symptom control and improve the quality of life  (QoL)  for 
subject s with  AERD, it would support the use of ifetroban as a therapeutic agent.  As such, the 
potential risk to subjects seems reasonable compared to the potential benefit.  
6 STUDY OBJECTIVES  & ENDPOINTS  
6.[ADDRESS_1053053] s with regards to:  pulmonary function, subject -
reported outcomes and QoL scales, pharmacodynamics responses based on TPr blockade, 
frequency and severity of exacerbations , sinus infections and the use of rescue medications and 
antibiotics.  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 16 6.3 Primary Efficacy Endpoint  
The primary endpoint of the study is the Change From Baseline  (CFB)  at Week 8  in SNOT -22 
score  (see Section 16.4 ). The primary analysis will compare this outcome for each study subject 
after treatment with ifetroban compared to placebo. The SNOT -[ADDRESS_1053054] of chronic rhinosinusitis (CRS) on QoL. This [ADDRESS_1053055] of CRS  on QoL. The 
questionnaire was found easy to use with a time to completion of seven  minutes and provided good 
discriminant validity ( Hopkins 2009 ). The SNOT -22 was validated and recommended for routine 
clinical practice. The  Minimal Clinically Important Difference (MCID) is ≥ 8.90. 
6.4 Secondary Efficacy Endpoints  and Other Exploratory Endpoints  
6.4.1 Second and Exploratory Efficacy Endpoints  
• Subject  reported symptoms:  
− Asthma Control Questionnaire (ACQ -7) 
− Total Nasal Symptom Score (TNSS)  
• FEV1 and peak Nasal Inspi[INVESTIGATOR_29330] ( PNIFR)  
• University of Pennsylvania Smell  Identification  test (UPSIT)  
• Frequency and severity of asthma exacerbations and chronic sinusitis  
• Use of  rescue medication and antibiotic use  
• Urinary leukotriene E4 and PG metabolite levels  
• Serum leukotriene B4 levels  
• Blood eosinophil count  
• Fractional exhaled Nitric oxide (FeNO)  
• Nasal epi[INVESTIGATOR_018], urinary and plasma eicosanoid levels  
6.4.2 Safety Endpoints  
The same safety endpoints will be applied across all study subjects. These include adverse 
events, vital signs, physical exams and clinical laboratory tests.  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053056] s per group.  
The clinical study will be conducted with 3 periods:  
• Screening period of up to three  weeks  
• Randomized ifetroban/placebo treatment period of eight  weeks  
• Post-treatment period for safety and efficacy of two weeks  
Figure  7-1 Study Design  
 
ACQ = Asthma Control Questionnaire ; FeNO  = Fractional exhaled nitric oxide ; FEV1 = forced expi[INVESTIGATOR_767918]; PBO = placebo; PD = pharmacodynamic; PNIFR = peak Nasal Inspi[INVESTIGATOR_29330] ; SNOT = Sino-
nasal Outcome Test ; TNSS = Total Nasal Symptom Score ; UPSIT = Smell Identification Test  

IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053057] ’s last visit/contact.  
7.2 Randomization and Blinding Conditions and Methods  
Subjects who meet all the inclusion and no exclusion  criteria during the Screening/Baseline Period  
will be randomized using a 1:[ADDRESS_1053058]’s case report form.   
7.3 Drugs and Dosages  
Oral ifetroban  is available as the sodium salt of the free acid and is for investigational use only . 
The drug is supplied as a capsule dosage form (size # 1, white  opaque) for oral administration. 
Ifetroban capsules are formulated as a dry powder blend and filled into hard gelatin capsules .  The 
formulation consists of i fetroban, mannitol, microcrystalline cellulose, crospovidone, magnesium 
oxide, colloidal silicon dioxide, and magnesium stearate.   Capsules are filled into high density 
polyethylene bottles and sealed with screw -cap closures.   Capsules are only available at one  
streng th of the sodium salt, i.e., 52.5  mg corresp onding to a free -acid dose of 5 0 mg.  
Matching placebo capsules are formulated as a dry powder blend filled into capsules.   The 
formulation consists of microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and 
magnesium stearate. Capsules are filled into high density polyethylene bottles and sealed with 
screw -cap closures.  
The bottles of oral Ifetroban or placebo will contain the following information on the label:  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 19  
 
 
 
 
 
 
Additionally, each individual bottle will be labelled with a unique numeric code that identifies the 
contents to the unblinded sponsor representative.  Four ( 4) capsules each of IMP (oral ifetroban or 
matching placebo) will be taken by [CONTACT_767945] . 
7.4 Selection of Study Population  
Study eligibility will be determined  by [CONTACT_767946].  
7.4.1 Inclusion Criteria  
Individuals who meet all of the following criteria are eligible for enrollment as study subjects:  
1. History of physician -diagnosed asthma  
2. History of nasal polyposis  
3. History of at least two reactions to oral aspi[INVESTIGATOR_767906] (cough, chest tightness, wheezing, 
dyspnea)  or one reaction that was life -threatening and required hospi[INVESTIGATOR_059] , or diagnosis 
of AERD via a physician -conducted challenge to aspi[INVESTIGATOR_767919]  
4. Stable asthma (post -bronchodilator FEV1 of ≥  60%, no glucocorticoid burst for at least 
two weeks prior to starting treatment, no hospi[INVESTIGATOR_767920] a dose >1000 µg 
fluticasone or equivalent daily ). 
5. ≥ [ADDRESS_1053059] 20 on the SNOT - 22 PLACEBO OR IFETROBAN  CAPSULES 50MG  
Quantity: 75 Capsules  
Instruction: Take capsules by [CONTACT_516913].  
Store at controlled room temperature, 20oC – 25oC (68oF – 77oF) 
Caution: New Drug -Limited by [CONTACT_767947].  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 20 7.4.2 Exclusion Criteria  
Individuals who meet any of these criteria are not eligible for enrollment as study subjects:  
1. Current smoking, defined as daily tobacco smoking in the last six months and at least one 
instance of tobacco smoking in the last three  months  
2. Current pregnancy or breastfeeding  
3. Use of oral or systemic steroids (e.g. prednisone or equivalent) > [ADDRESS_1053060] two weeks before starting treatment  
5. Less than 12 months of allergy shots (maintenance dose of allergy shots are allowed if 
treatment  duration exceeds 12 months) . Less than 1 month of 5-lipoxygenase inhibitors 
(e.g. zileuton) and/or leukotriene receptor antagonists  (e.g. montelukast) . 
6. Any use of nonsteroidal anti -inflammatory drugs (NSAIDs) or any drug that inhibits the 
cyclooxygenase enzyme in the last two weeks before starting treatment  
7. History of bleeding diathesis or use of anticoagulant or antiplatelet drugs in the last [ADDRESS_1053061] two weeks before starting treatment 
(maintenance dose of allergy shots are allowed if treatment duration exceeds 12 months) . 
Biologics/immunotherapi[INVESTIGATOR_767921].  
9. Endoscopic sinus surgery / polypectomy within the past three  months  
10. Previously treated in any clinical trial with  ifetroban  
11. Previously treated with other  investigational drugs within eight  weeks or five half-lives, 
whichever is longer, before screening  
12. Conditions/concomitant disease which make the  participant  unevaluable for the efficacy 
endpoints  
7.[ADDRESS_1053062]  diary and recorded in the 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 21 appropriate C ase Report Form ( CRF ).  All subjects must be protected by [CONTACT_767948]:  
- Established use of oral, injected or implanted hormonal contraceptive  
- "Double barrier" methods (i .e., Double Intrauterine device with copper or intrauterine 
system with progestogen and barrier contraceptive [condom, diaphragm or cervical/vault 
caps] used with spermicide [foam, gel, film, cream or suppository])  
- Female sterilization (e .g., tubal occlusion, hysterectomy or bilateral salpi[INVESTIGATOR_1656])  
- Male sterilization with post -vasectomy documentation of the absence of sperm in the 
ejaculate; for female subject s enrolled in the study, the vasectomized male partner should be 
the sole partner for that subject  
The following concomitant medications are allowed.  
a. Inhaled, oral or nasal corticosteroids: subjects on a stable dose ≥ 30 day  prior to starting 
IMP.  Use of oral or systemic steroids  (e.g. prednisone or equivalent) must be at a stable 
dose ≤ [ADDRESS_1053063]  diary and recorded in the appropriate CRF.  
b. Inhaled long -acting beta -adrenergic agonists and anti-muscarinic  receptor antagonists : 
subjects may enter the trial on such medications base d on the underlying condition. 
Modifications are allowed if symptoms require a change in dose or frequency. All use must 
be tracked in the subject  diary and recorded in the appropriate CRF.  
c. Inhaled short -acting beta -adrenergic agonists (PRN use): subjects  may enter the trial on 
such medications based on the underlying condition.  All use must be tracked in the subject  
diary and recorded in the appropriate CRF.  
d. Nasal budesonide rinses  
e. Short -term use of antibiotics (< 2 weeks)  
f. Daily use of l ong-acting antihistamines  are prohibited two weeks before starting treatment 
however subjects may administer such medications on an as-needed basis only  based on 
the underlying condition. All use must be tracked in the subject  diary and recorded in the 
appropriate CRF.  
g. Maintenance dose of allergy shots if treatment duration exceeds 12 months  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 22 h. Use of 5-lipoxygenase inhibitors (e.g. zileuton) and leukotriene receptor antagonists  (e.g. 
montelukast)  if subjects are on a stable dose for ≥ 30 days . 
i. Use of biologics/immunotherapi[INVESTIGATOR_767922] a stable dose 
for ≥ three months.  
7.[ADDRESS_1053064] -treatment periods:  
• Use of oral or systemic steroids  (e.g. prednisone or equivalent)  > [ADDRESS_1053065] 
four weeks before starting treatment  
• Daily u se of long -acting antihistaminesin the last two weeks before starting treatment.  
Please note: daily use of long -acting antihistamines is prohibited  however subjects may 
administer such medications on an as-needed basis only  based on the underlying 
condition. All use must be tracked in the subject  diary and recorded in the appropriate CRF.  
• Any use of nonsteroidal anti -inflammatory drugs (NSAIDs) or any drug that inhibits the 
cyclooxygenase enzyme in the last two weeks before starting treatment  
• Use of w arfarin or any other antiplatelet or anticoagulant medications in the last two weeks 
before starting treatment  
• Long -term use of systemic antibiotics (>  2 weeks)  
• Any immunosup pressive  treatment including but not limited to methotrexate, cyclosporine,  
mycophenolate, tacr olimus, gold, penicillamine, sulfasalazine, hydroxychloroquine,  
azathioprine  and cyclophosphamide  (maintenance dose of allergy shots are allowed if  
treatment duration exceeds 12 months) . Biologics/immunotherapi[INVESTIGATOR_767923].  
• Endoscopic sinus surgery / polypectomy within the past three  months prior to starting 
treatment  
7.[ADDRESS_1053066] of decreasing the maximum serum concen tration (C max) (average of 80 -90%), 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 23 prolonging the time of maximum plasma concentration (T max) (8-12 fold), and decreasing the area 
under the concentration time -curves from time zero to infinity (AUC 0-∞) of ifetroban  (average of 
25-35%) compared to the fasting state.  
For this reason , ifetroban and placebo should be  taken at least 30 minutes before a meal or six 
hours after a meal.   
8 STUDY VISITS AND  PROCEDURES  
8.1 Overview – Schedule of Time and Events  
This [ADDRESS_1053067] of a three -week Screening  Period ( Week -3 to Week 0 ), an 8-week 
Treatment Period ( Week 0 to Week 8) and a two -week Post-treatment  Period ( Week 8 to Week 10 ). 
The study visits occur on the planned dates relative to the first dose of IMP as scheduled. The visit 
schedule should be adhered to within the ± [ADDRESS_1053068] dose of IMP  is respected. Subjects  that fail 
screening  for exclusion criteria, for example concomitant medications, acute illness (upper 
respi[INVESTIGATOR_575197]), required drug -specific discontinuation periods or laboratory tests, may 
be rescreened  for study eligibility one additional time.  
8.1.1 Screening  Period  
The Screening  Period is defined as the three-week  period prior to Week  0 (IMP administration) . 
Before  the initiation of study -specific screening assessments, the subject  must be given a complete 
explanation of the purpose of the study  and evaluations that will be made as part of the study. 
Subsequently, the  subject  must sign and receive a copy of an Informed Consent Form that was 
approved by [CONTACT_291288] B oard (IRB)/Independent Ethics Committee (IEC) . Once 
informed consent has been obtained, the eligibility of the subject  to participate in this study will 
be determined by [CONTACT_767949] 
7.4. Screening  Period assessments will also be performed to determine eligibility. Only eligible 
subject s will be randomized to receive  IMP at Week  0. 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053069] ’s eligibility for this study  
(Table  8–1) during the Screening Period  (Week -3 to Week 0) : 
• Informed Consent  
• Interview to collect subject medical history, including but not limited to , disease history 
(including asthma history, number of asthma exacerbations in the previous year, 
hypersensitivity to aspi[INVESTIGATOR_162882]), surgical history (including the number and 
dates of previous nasal polypectomies ), recently discontinued  and concomitant 
medications ( include all  background therapy for AERD).  
• Demographic data  
• Administer SNOT -22. 
• Perform spi[INVESTIGATOR_767924] s stable asthma  (FEV1 ≥  60% of predicted 
normal and has not experienced any exacerbation  requiring treatment with ≥ 1 system ic 
(oral or parenteral) steroid  bursts  for worsening asthma and/or hospi[INVESTIGATOR_767925]/urgent medical care visit  for worsening asthma in the previous three  months or 
are on a dose of inhaled corticosteroids > 1000 µg fluticasone or equivalent  daily ). 
• Obtain fasting blood samples for screening clinical laboratory determinations:  
o Hematology: To include hemoglobin, hematocrit, platelet count, total white blood 
cell count with five -part differential count, and total red blood cell count.  
o Serum chemistry: To include creatinine, blood urea nitrogen, glucose, uric acid, 
total cholesterol, total protein, albumin, total bilirubin, alanine aminotransferase, 
aspartate  aminotransferase, alkaline phosphatase, electrolytes (sodium, potassium, 
chloride),  bicarbonate, and creatine phosphokinase.  
o Prothrombin time (PT) and international normalized ratio (INR)  
• Review entry criteria to assess eligibility with special attention to verify the following:  
o History of at least two reactions to oral aspi[INVESTIGATOR_767926] (cough, chest 
tightness, wheezing, dyspnea)  or one reaction that was life -threatening and required 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053070] five years before starting treatment  
o Use of oral or systemic steroids  (e.g. prednisone or equivalent) > [ADDRESS_1053071] two weeks before starting treatment.  Subjects on 5-lipoxygenase inhibitors 
(e.g. zileuton) and /or leukotriene receptor antagonists (e.g. montelukast) must be 
on a stable dose for ≥ [ADDRESS_1053072] 20 on the SNOT - 22 
• Perform physical  examination  including vital signs [blood pressure, heart rate, respi[INVESTIGATOR_11943], body temperature, weight (kg), height (cm)]  
• Obtain pregnancy test if  female of child -bearing potential (pre-menopausal female 
biologically capable of becoming pregnant).  Confirm s ubject is protected by [CONTACT_767950]:  
- Established use of oral, injected or implanted hormonal contraceptive  
- "Double barrier" methods (i .e., Double Intrauter ine device with copper or intrauterine 
system with progestogen and  barrier contraceptive [condom, diaphragm or cervical/vault 
caps] used with spermi cide [foam, gel, film, cream or suppository])  
- Female sterilization ( e.g., tubal occlusion, hysterectomy or bilateral salpi[INVESTIGATOR_1656])  
- Male sterilization with post -vasectomy documentation  of the absence of sperm in the 
ejaculate; for female subject s enrolled in  the study, the vasectom ized male partner should 
be the sole partner for that subject  
• Dispense subject  diary, provide instructions for daily use and remind subject  to bring it to 
the next visit.  
• Schedule appointment for next visit  
8.1.2 Treatment Period  
Week 0 Start of Treatment Visit – Randomization  
After the t hree-week Screening Period, subjects will come into the site for Week 0 Visit.  
• Interval history, record baseline signs and symptoms , record all medication use with start 
date and dose and check for prohibited medications.  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 26 • Perform a limited physical exam with vital signs  (blood pressure, heart rate, respi[INVESTIGATOR_11943], body temperature, weight)  
• Administer TNSS, ACQ -7, and SNOT -22 
• Obtain spi[INVESTIGATOR_767927] e lectronic CRF  (eCRF ) 
• Reconfirm eligibility based on review of Inclusion/Exclusion criteria  
A subject will be considered to have failed screening if entry criteria are not met  and should be 
discontinued . 
If the subject meets all inclusion and does not meet any exclusion criteria:  
• Subject will be randomized  
• PNIFR and FeNO will be recorded  
• Perform serum/ urine pregnancy test (for women of childbearing potential) . Confirm 
subject is protected by [CONTACT_767951]:  
- Established use of oral, injected or implanted hormonal contraceptive  
- "Double barrier" methods ( i.e., Double Intrauter ine device with copper or intrauterine 
system with progestogen and  barrier contraceptive [condom, diaphragm or cervical/vault 
caps] used with spermi cide [foam, gel, film, cream or suppository])  
- Female sterilization ( e.g., tubal occlusion, hysterectomy or bilateral salpi[INVESTIGATOR_1656])  
- Male sterilization with post -vasectomy documentation  of the absence of sperm in the 
ejaculate; for female subject s enrolled in the study, the vasectom ized male partner should 
be the sole partner for that subject  
• Perform blood sampling (prior to administration of IMP) for clinical laboratories : 
hematology, chemistry, PT, and INR . 
Note: Clinical laboratory testing at Week 0 Visit is limited to biomarkers in serum and plasma  if 
screening labs were performed within three weeks of starting IMP treatment . 
• Collect u rine and blood sample s for eicosanoi d metabolites.  
• Collect n asoabsorptive matrix for eicosanoid measurements.  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 27 • Conduct a smell test (UPSIT)  
• Collect data from subject  diary and remind subject  to record daily medication usage 
including IMP, exacerbations, rescue medication or antibiotic usage, if applicable, twice 
daily TNSS (AM and PM) and to bring their diary to the next visit  
• Pre-IMP Dietary Assessment  
• Dispense IMP and administer IMP  
• Commence AE reporting  
• Schedule appointment for next visit  
Treatment Period ( Week 0 to Week 8):   Subjects will take ifetroban or placebo daily for eight  
weeks. There will be a telephone encounter one week into this Treatment Period to ensure safety 
and confirm that baseline asthma symptoms have not worsened.  
Week 4  Treatment Visit  
After four weeks of treatment , subjects will return  to the site for Week 4 Treatment  Visit.  
• Record all medication use with start date and dose and check for prohibited medications.  
• Inquire about AEs/ Serious Adverse Events ( SAEs ) and IMP tolerability  
• Perform a limited physical exam with vital signs  (blood pressure, heart rate, respi[INVESTIGATOR_11943], body temperature, weight)  
• Administer TNSS, ACQ -7, and SNOT -22 
• Obtain spi[INVESTIGATOR_038] , PNIFR and FeNO  
• Perform serum/ urine pregnancy test (for women of childbearing potential)  Confirm s ubject 
is protected by [CONTACT_767952]:  
- Established use of oral, injected or implanted hormonal contraceptive  
- "Double barrier" methods ( i.e., Double Intrauter ine device with copper or intrauterine 
system with progestogen and  barrier contraceptive [condom, diaphragm or cervical/vault 
caps] used with spermi cide [foam, gel, film, cream or suppository])  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 28 - Female sterilization ( e.g., tubal occlusion, hysterectomy or bilateral salpi[INVESTIGATOR_1656])  
- Male sterilization with post -vasectomy documentation  of the absence of sperm in the 
ejaculate; for female subject s enrolled in the study, the vasectom ized male partner should 
be the sole partner for that subject  
• Collect u rine and blood sample s for eicosanoi d metabolites.  
• Collect n asoabsorptive  matrix for eicosanoid measurements.  
• Conduct a smell test (UPSIT)  
• Review subject  diary for IMP compliance, content and completeness; collect data from 
subject  diary and remind subject  to continue record ing daily medication usage including 
IMP, time of meals and doses , exacerbations, rescue medication or antibiotic usage (if 
applicable ), twice daily TNSS (AM and PM) and to bring their diary to the next visit  
• Dispense IMP and administer IMP  
• Schedule appointment for next visit  
Week 8  End of Treatment Visit  
After four additional weeks of treatment , subjects will return  to the site for Week 8 End of 
Treatment  Visit.  
• Record all medication use with start date and dose and check for prohibited medications.  
• Inquire about AEs/SAEs and IMP tolerability  
• Perform a limited physical exam with vital signs  (blood pressure, heart rate, respi[INVESTIGATOR_11943], body temperature, weight)  
• Administer TNSS, ACQ -7, and SNOT -22 
• Obtain spi[INVESTIGATOR_038],  PNIFR and FeNO  
• Perform serum/ urine pregnancy test (for women of childbearing potential) . Confirm 
subject is protected by [CONTACT_767951]:  
- Established use of oral, injected or implanted hormonal contraceptive  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 29 - "Double barrier" methods ( i.e., Double Intrauter ine device with copper or intrauterine 
system with progestogen and  barrier contraceptive [condom, diaphragm or cervical/vault 
caps] used with spermi cide [foam, gel, film, cream or suppository])  
- Female sterilization ( e.g., tubal occlusion, hysterectomy or bilateral salpi[INVESTIGATOR_1656])  
- Male sterilization with post -vasectomy documentation  of the absence of sperm in the 
ejaculate; for female subject s enrolled in the study, the vasectom ized male partner should 
be the sole partner for that subject  
• Perform blood sampling for clinical laboratories : hematology , chemistry, PT,  and INR. 
• Collect u rine and blood sample s for eicosanoi d metabolites.  
• Collect n asoabsorptive  matrix for eicosanoid measurements.  
• Conduct a smell test (UPSIT)  
• Review subject  diary for IMP compliance, content and completeness; c ollect data from 
subject  diary and remind subject  to continue recording daily medication usage, time of 
meals and doses, exacerbations, rescue medication or antibiotic usage (if applicable ), twice 
daily TNSS (AM and PM) and to bring their diary to the next visit  
• Schedule appointment for next visit  
8.1.[ADDRESS_1053073]-treatment  Visit.  
• Record all medication use with start date and dose and check for prohibited medications.  
• Inquire about AEs/SAEs  
• Perform a limited physical exam with vital signs  (blood pressure, heart rate, respi[INVESTIGATOR_11943], body temperature, weight)  
• Administer TNSS, ACQ -7, and SNOT -22 
• Obtain spi[INVESTIGATOR_038],  PNIFR and FeNO  
• Perform blood sampling for clinical laboratories  if abnormal at Week 8 only : 
hematology , chemistry, PT,  and INR. 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 30 • Collect u rine and blood sample s for eicosanoi d metabolites.  
• Collect n asoabsorptive  matrix for eicosanoid measurements.  
• Conduct a smell test (UPSIT)  
• Review subject  diary for content and completeness; collect data from subject  diary  
• Propose the optional qualitative self -assessment of the treatment to the subject  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 31 Table  8–1 Schedule of Treatment & Events  
  Screening Period  Treatment Period  Post-treatment  
Period  
  Visit(s)   Visit  Phone  
Call Visit  Visit  Visit  
  Week -3 to Week 0  Week 0  Week 1  Week 4  
(± 5 days)  Week 8  
(± 5 days)  Week 10  
(± 5 days)  
Informed Consent  X          
Inclusion/Exclusion Criteria  X          
Medical & Surgical History  X          
Subject Demography  X          
Physical Exam with vital signs  X      
Limited Physical Exam with vital signs   X  X X  X 
Spi[INVESTIGATOR_038]  (FEV1)   X X  X  X  X 
PNIFR and FeNO    X  X X  X 
Pregnancy Test ( Serum/ Urine )a   X X   X X  X 
Hematologyb  X Xd   X   Xe 
PT, INR, Chemistryc  X Xd   X  Xe 
SNOT -22, TNSS, ACQ -[ADDRESS_1053074] (UPSIT)    X  X X X 
Collect urine & blood  for eicosanoid levels   X  X X X 
Collect nasoabsorptive matrix for eicosanoid 
levels    X  X X X 
Self-assessment of the treatment (optional)       X   
Dispense IMP    X  X    
IMP Dosing    I------- -----Continual Once Daily Dosing (200 mg/day) --------- I   
Record Concomitant Medications  I------------------------------------- ---------------------------- Continual ------------------- -------------------------------------- I 
AE/SAE Recording (if any)    I--------------------------------- ---------- Continual ---------- ---------------------------------------- I 
Dispense, review and/or collect subject  diary   X  X X  X 
a) For women of childbearing potential; b) Hemoglobin , hematocrit, platelet count, total white blood cell count with five -part differential count, and total red blood cell count; c) Creatinine, 
blood urea nitrogen, glucose, uric acid, total cholesterol, total protein, albumin, total bilirubin, alanine aminotransferase , aspartate aminotransferase, alkaline phosphatase, electrolytes 
(sodium, potassium, chloride), bicarbonate, and creatin e phosphokinase ; d) Week [ADDRESS_1053075] to be repeated if Screening labs were performed withi n 
3 weeks of starting IMP ; e) Week 10 hematology, chemistry, PT and INR only performed for abnormal labs at Week 8 ; f) SNOT -22 only at Screening; All 3 questionnaires are required at 
subsequent visits.  
ACQ -7 = Asthma Control Questionnaire ; AE = adverse event; FEV1 = Forced Expi[INVESTIGATOR_1814] 1 Second ; FeNO = Fractional exhaled Nitric oxide ; IMP = Investigational Medicinal 
Product ; INR = international normalized ratio ; PNIFR = Peak Nasal Inspi[INVESTIGATOR_29330] ; PT = prothrombin time; SAE = serious adverse event; SNOT = Sino-nasal Outcome Test ; TNSS  
= Total Nasal Symptom Score ; UPSIT  = Smell Identification Test  
 
 
 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053076] Discontinuation  
Subjects will be encouraged to complete the study; however, they may voluntarily withdraw at  any 
time.  The Investigator will provide a report in the CRF describing the reason for discontinuation.  
If a subject withdraws before completion, every effort should be made to complete the assessments 
scheduled during the final scheduled assessment.     
A subject may be terminated early  from the study for the following reasons:  
• The subject elects to withdraw consent from all future study activities, including follow -
up. 
• The subject is “lost to follow -up” (i.e., no further follow -up is possible because attempts to 
reestablish contact [CONTACT_73880]).  
• The subject dies.  
• The subject develops a medical condition or is started on new medication(s) prohibited by 
[CONTACT_767953], in the 
opi[INVESTIGATOR_871], may pose additional risks from participation in the study, may 
interfere with the subject’s ability to comply with study requirements or that may impac t 
the quality of the data obtained from the study.  
• If, in the course of an asthma exacerbation, a study investigator decides to discontinue 
study medication ( ifetroban/placebo ), the subject  will be withdrawn from the study.  
• In addition , subjects must be withdrawn from the study if any of the following occur:  
o Any serious adverse event related to study medication ( ifetroban /placebo or aspi[INVESTIGATOR_248]) 
or to a study procedure  
o Serious arrhythmia requiring therapy  
o Thrombocytopenia < 50 x 109/L 
o Anemia (a fall in baseline hemoglobin of 10% or more)  
o Gastrointestinal bleeding  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 33 o Pregnancy  
Subjects  who are prematurely terminated from the study will be followed to monitor safety for a 
minimum of 30 days or until resolution of the disqualifying event, whichever is longer, or until the 
Independent Safety Monitor, the CPI [INVESTIGATOR_767928] -up is complete.  
Subjects  with early termination from this study will not be replaced.  
9.2 Study or Site Termination  
If the Sponsor , Investigator, Independent Safety  Monitor, Study Monitor, or appropriate regulatory 
officials discover conditions arising during the study that indicate that the study should be halted 
or that the study center should be terminated, this action may be taken after appropriate 
consultation among the Sponsor , Investigator, Independent Safety  Monitor, and Study Monitor.   
Conditions that may warrant termination of the study include, but are not limited to, the following:  
• The discovery of an unexpected, serious, or unacceptable risk to the subjects enrolled in 
the study  
• A decision on the part of the Sponsor  to suspend or discontinue testing, evaluation, or 
development of the product  
• A study conducted at a single study site or a single study site in a multicenter study may 
also warrant termination under the following conditions:  
o Failure of the Investigator to enroll subjects into the study at an acceptable rate  
o Failure of the Investigator to comply with pertinent regulations of appropriate 
regulatory authorities  
o Submission of knowingly false information from the research facility to the 
Sponsor , Study Monitor, or appropriate regulatory authority  
o Insufficient adherence to protocol requirements  
Study termination and follow -up will be performed in compliance with the conditions set forth in 
the International Conference on Harmonization (ICH) sixth efficacy publication (E6) on Good 
Clinical Practice, section 4.12, ICH E6 4.13, ICH E6 5.20, and ICH E6 5.21 . 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 34 10 ADVERSE EVENTS  
Adverse events will be captured in the CRF for this study.   
10.1 Definitions  
10.1.1  Adverse Event Definitions  
Adverse events are defined according to ICH Harmonized Tripartite Guideline E2A  and 21 CFR 
312.32 . 
Adverse event (AE) – is any untoward medical occurrence in a subject  or clinical trial subject 
administered a trial product and which does not necessarily have a causal relationship with this 
treatment.  
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding, for example), symptom, or disease temporally associated with the use of a 
medicinal product, whether or not considered related to the medicinal  product.  
The following is not considered  or documented as  an AE  in study records : 
• Pre-planned procedure (documented as concomitant illness on the CRF at screening) unless 
the condition for which the procedure was planned has worsened from the first trial -related 
activity after the subject has signed the informed consent form.  
• Pre-existing conditions found as a result of screening procedures  unless the condition 
worsens during treatment . 
• Events which are pre-defined as part of the efficacy analysis. However, if events are serious 
as defined below, events must be reported as such.  
Serious adverse event (SAE) – is any untoward medical occurrence or effect that at any dose: 
results in death; is life -threatening (this refers to an event in which the subject was at risk of death 
at the time of the event; it does not refer to an event th at hypothetically might have caused death 
if it was more severe); requires in -subject  hospi[INVESTIGATOR_6929]; results in persistent or significant disability or incapacity; is a congenital anomaly 
or birth defect; is ju dged medically important (this refers to an event that may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_059], but may jeopardize the subject or may require 
intervention to prevent one of the other outcomes listed).  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 35 10.1.2  Adverse Event Assessment Definitions  
Severity  
The maximum severity of an adverse event is assessed by [CONTACT_130691]:  
• Mild: Transient symptoms, no interference with the subject’s daily activities.  
• Moderate: Marked symptoms, moderate interference with the subject’s daily activities.  
• Severe: Considerable interference with the subject’s daily activities, unacceptable.  
Relationship  
The causal relationship between an adverse event and the trial product is assessed by [CONTACT_221679]:  
• Probable: Good reasons and sufficient documentation to assume a causal relationship.  
• Possible: A causal relationship is conceivable and cannot be dismissed  
• Unlikely: The event is most likely related to an etiology other than the trial product.  
An adverse event is considered causally related to the use of the trial product when the relationship 
assessment is probable or possible. Events assessed as unlikely related to the use of trial product 
will generally be considered as having no relationship to treatment.  
Outcome  
The outcome of an adverse event is assessed by [CONTACT_229733]:  
• Recovered: Fully recovered, or by [CONTACT_767954] t he first trial -related activity.  
• Recovering: The condition is improving and the subject is expected to recover from the 
event. This term should only be used when the subject has completed the trial.  
• Recovered with sequelae: As a result of the AE the subject suffered persistent and 
significant disability/incapacity (e .g. became blind, deaf, paralyzed). Any AE recovered 
with sequelae should be classified as SAE.    
• Not recovered: The subject’s condition has not improved and the symptoms are unchanged  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 36 • Fatal  
• Unknown: The subject’s condition is unknown. This term should only be used when no 
other definition is possible (e.g. the subject is lost to follow -up). 
10.[ADDRESS_1053077] inform the IRB in accordance with local requirements in force and the ICH 
guidelines for GCP and the Food and Drug Administration ( FDA ) Title [ADDRESS_1053078] been resolved.  
For cases of chronic conditions, follow -up until “recovered” is not required. After the subject has 
completed the trial, these cases can be closed with the outcome “recovering” or “not recovered”.  
All other non -serious adverse events must be followed until the outcome of the event is 
“recovering” (for chronic conditions), “recovered” or until  the last subject contact/visit/end of 
post-treatment follow -up period, whichever comes first, and until all queries related to the adverse 
event have been resolved.  
Follow -up of Serious Adverse Events  
All adverse events classified as serious should be followed until the outcome of the event is 
“recovered”, “recovered with sequelae”,  or “death” and until all queries have been resolved.  For 
cases of chronic conditions and cancer, follow -up until “recovered”, “recovered with sequelae” or 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 37 “death” is not required. After the subject has completed the trial, these cases can be closed with 
the outcome “recovering” or “not recovered”.  
11 STATISTICAL METHODS AND DATA ANALYSIS  
The following text provides general description of the statistical methodology for the assessment 
of efficacy, safety, and tolerability of  200 mg /day of oral ifetroban in this double -blind placebo -
controlled study in subjects with symptomatic AERD . Details of the statistical analyses will be 
provided in the Statistical Analysis Plan, which will be finalized prior to database lock and 
unblinding.   All recorded data will be listed.  
11.1 Sample Size Determination  
Thirty -eight subjects per group will provide 90% power for the comparison of ifetroban and 
placebo  with respect to the change from baseline in SNOT -22 scores at Week 8 (two-sided, level 
0.05) , assuming a common standard deviation of [ADDRESS_1053079]-treatment  Period.  
11.2.2    Intent -to-Treat Population  
The Intent -To-Treat (ITT) Population will consist of all treated subjects  with at least one post -
baseline assessment of SNOT -22. 
11.2.3    Per Protocol Population  
The Per Protocol (PP) P opulation will consist of all subjects in the ITT population with no major 
protocol violations , including violation of inclusion or exclusion criteria or insufficient dosing . 
Inclusion of subjects in the PP Population  will be determined prior to unblinding.  
11.[ADDRESS_1053080] to age group, gender, 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 38 region, race, baseline SNOT -22, baseline TNSS , baseline ACQ -7 and selected biomarkers prior to 
the study. The details will be provided in the S tatistical Analysis Plan. 
11.4 Randomization  
Subjects will be randomized using a 1:[ADDRESS_1053081] of the imputation technique(s).  
11.6 Data  Analysis Plan   
11.6.1   Demographic  and Baseline Parameters  
Demographic and baseline characteristics  will be summarized using descriptive statistics  or 
frequency tables, by [CONTACT_6654].  
11.6.2    Exposure  and Compliance  
Exposure and c ompliance will be summarized for the Safety Population  by [CONTACT_14459]. Comments recorded on the Study Drug Accountability CRF page will not be applied in 
the computation of compliance.   
Exposure is the duration (days) of treatment, computed as : 
Exposure  = Date of Final D ose- Date of Baseline Visit + 1.   
Treatment compliance will be calculated as:  
Compliance (%) = 100* (Total Number of Capsules  Dispensed -Total Number of Capsules 
Returned)/(4*Exposure).  
 
11.6.3  Efficacy  Analyses  
All hypothesis tests will be performed at the 0.05 level . Analyses of the primary and secondary 
efficacy variables will be performed using both the ITT and PP  Populations.  Corresponding 
summary statistics will be presented  for all efficacy analyses.  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 39 [IP_ADDRESS]  Primary Analysis  
The primary efficacy endpoint is the CFB in SNOT -22 score and the primary analysis is  the 
analysis  of CFB in S NOT -22 at Week 8 , using Analysis of Covariance (ANCOV A) , with SNOT -
22 at Baseline included as the only covariate.  
[IP_ADDRESS]  Analysis of secondary endpoints  
CFB in ACQ -7 and CFB in TNSS at Week  8 will be analyzed  using ANCOV A , with the 
corresponding value at Baseline included as the only covariate.  These variables, as well as CFB in 
SNOT -22, at Week 4  will also be analyzed as ancillary analyses.   
Analyses of CFB for other continuous efficacy variables will be performed at Weeks 4 and 8 in the 
same manner using ANCOV A  with the corresponding value at Baseline included as the only 
covariate.  
Any improvement in SNOT -22, ACQ -7, and TNSS (Yes or No) at Weeks 4 and 8  will be analyzed 
using the normal approximation to the binomial distribution, assuming unequal variances.  
11.6.4     Safety Parameters  
All safety data will be summarized.  AEs will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA) (Version 9.0 or later ). All T reatment Emergent Adverse Events (TEAEs ) 
will be summarized by [CONTACT_1570]. Counts and percents will be presented by [CONTACT_767955] (SOC) and preferred term as defined in MedDRA.    
The preferred terms and SOCs will be summarized in the following set of tables:  
• All AEs;  
• All AEs  by [CONTACT_767956];  
• All AEs by [CONTACT_767957].  
The frequencies and percentages of AEs will be tabulated. Incidence, relation to study medication, 
and severity will be summarized.  
Physical examination findings , laboratory parameters , vital signs, FEV1 , weight, and 
corresponding changes from Baseline, as appropriate,  will be summarized using descriptive 
statistics  at each visit . 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 40 12 STUDY MANAGEMENT AND DATA COLLECTION  
12.1 Confidentiality  
All information regarding the nature of the proposed investigation provided by [CONTACT_767958] (with the exception of information required by [CONTACT_401162], the subject, or the appropriate regulatory authority) must be kept in 
confidence by [CONTACT_737].  
The anonymity of participating subjects must be maintained. Subjects will be identified by [CONTACT_507670]. 
Documents that will not be submitted to the Study Monitor and that ident ify the subject (e.g., the 
signed informed consent document) must be maintained in strict confidence by [CONTACT_737], 
except to the extent necessary to allow auditing by [CONTACT_61476], the Study 
Monitor, or Sponsor  representative s. 
12.2 Source Documents  
Source data are contained in source documents.  Examples of these original documents, and data 
records include: hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ 
diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copi[INVESTIGATOR_10379], 
microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject files, and 
records kept at the pharmacy, at the laboratories, and at medico -technical departments involved in 
the clinical trial . 
12.[ADDRESS_1053082] (accordi ng to Sponsor instructions) all observations and other data pertinent 
to the clinical investigati on in a timely manner. All CRFs should be completed in their entirety in 
a neat, legible manner to en sure accurate interpretation of data.  
Should a correction be made, the corrected information will be e ntered in the e -CRF overwriting 
the initial information. An audit trail allows  for identifying the modification.  
Data are available within the system to the Sponsor as soon as they are entered in the e -CRF.  
 
The computerized handling of the data by [CONTACT_767959]. The requests with their responses will be managed through the eCRF.    
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 41 12.4 Records Retention  
According to CFR21 312 .62 (c) and ICH E6 4.[ADDRESS_1053083] for the 
indication under s tudy, if no application is to be filed or if the application is not approved for such 
indication, until two years after the investigation is discontinued and FDA is notified.  It is the 
sponsor’s responsibility to inform the investigator as to when these do cuments no longer need to 
be retained.  No study documents will be destroyed or moved to a new location without prior 
written approval from the Sponsor .  If the Investigator relocates, retires, or withdraws from the 
clinical study for any reason, all records required to be maintained for the study should be 
transferred to an agreed upon designee, such as the Study Monitor, another Investigator, or the 
institution where the study was conducted . 
13 STUDY MONITORING, AUDITING, AND INSP ECTING  
13.1 Study Monitoring Plan  
The progress of the study will be monitored by [CONTACT_331614]:  
• Periodic o n-site visit (s) 
• Telephone communications , as needed,  among the Investigator, Clinical Monitor and 
Medical Monitor  
• Review  of CRFs and clinical records  
[ADDRESS_1053084] (or the subject’s legal 
guardian/representative) before performing any Screening Period evaluations.  The signed 
informed consent document will be retained by [CONTACT_737], and a copy will be given to the  
subject or subject’s legal guardian/representative.  The informed consent document, which is 
prepared by [CONTACT_737], must have been reviewed and approved by [CONTACT_767960]’s IRB before the initiation of the study.  The document must contain the 20  elements 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 42 of informed consent described in ICH E6 4.8  (Appendix 1 6.1).  Appendix  16.[ADDRESS_1053085] s of 
appropriate intellectual maturity should provide written informed assent, as determined by [CONTACT_230991]’s IRB or local legal requirement . 
14.[ADDRESS_1053086] the safety of subjects or changes 
that alter the scope of the investigation, the scientific quality of the study, the experimental design , 
dosages, assessment variable(s), the number of subjects treated, or the subject selection criteria.  
Such changes must be prepared as a protocol amendment by [CONTACT_767961] , Investigator, and the Study Monitor.  A protocol 
amendment must receive IRB approval before implementation.  In parallel with the IRB approval 
process, the protocol amendment will be submitted to the appropriate regulatory authority as an 
amendment to the regulatory submission under which the study is being conducted.  If a protoc ol 
amendment requires changes in the informed consent document, the revised informed consent 
document prepared by [CONTACT_507673] , Study Monitor, and the 
IRB.  
Emergency departures from the protocol that eliminate an apparent immediate hazard to a 
particular subject and that are deemed crucial for the safety and well -being of that subject may be 
instituted for that subject only.  The Investigator or other attendi ng physician also will contact [CONTACT_767962] a departure.  These departures do not 
require pre -approval by [CONTACT_1201]; however, the IRB and Medical Monitor must be notified in 
writing as soon as possible after the  departure has been made.  In addition, the Investigator will 
document in the subject’s CRF the reasons for the protocol deviation and the ensuing events . 
14.3 Study Files  
Documentation concerning Investigator data, IRB data, and clinical laboratory data is required 
before shipment of oral ifetroban  to the study site ( Appendix  16.2).  Copi[INVESTIGATOR_767929], such as the Investigator’s Brochure and Responsibilities and 
Obligations of Investigators and Sponsor s (Appendix 16.3.2), will be kept on -site in a special study 
file. This file also will contain drug accountability (receipt/dispensing) records, 
Sponsor /Investigator correspondence, IRB correspondence, changes to the protocol, information 
regarding monitoring activities, subject  exclusion records, biological samples records, and CRFs.  
Investigator data, including FDA Form  1572 and statement of qualifications for each Investigator, 
are provided in Appendix 16.3.2. 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 43 15 REFERENCES  
Arm JP, O'Hickey SP, Spur BW, et al. Airway responsiveness to histamine and leukotriene E4 in 
subjects with aspi[INVESTIGATOR_248] -induced asthma. Am.  Rev. Respir.  Dis. 1989 Jul;140(1):[ADDRESS_1053087] of subcutaneous dupi[INVESTIGATOR_767930]: a randomized clinical trial. JAMA. 
2016 Feb 2; 315(5): [ADDRESS_1053088] s with aspi[INVESTIGATOR_248] -exacerbated respi[INVESTIGATOR_3765]. J. Allergy Clin.  Immunol. 2003 
Jan;111(1):180 -6. 
Bochenek G, Nagraba K, Nizankowska E,  et al. A controlled study of 9  alpha,  11 beta-PGF2 (a 
prostaglandin D2 metabolite) in plasma and urine of subject s with bronchial asthma and healthy 
controls after aspi[INVESTIGATOR_437782]. J Allergy Clin Immunol 2003 Apr;  111(4):743 -9. 
Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D2: A dominant mediator of aspi[INVESTIGATOR_248] -
exacerbated respi[INVESTIGATOR_3765]. J.Allergy Clin.  Immunol. 2015 Jan;135(1):245 -52. 
PMCID:PMC4289104 . 
Celikel S, Stevenson D, Erkorkmaz U, et al. Use of nasal inspi[INVESTIGATOR_767931] -induced respi[INVESTIGATOR_560088]. Ann Allergy Asthma Immunol 2013  111:[ADDRESS_1053089]. 
Clin Otolaryngology. 2009; 34: 447 -454. 
Juniper EF, O'By[CONTACT_21143], Guyatt GH, Ferrie PJ, King DR. Development and validation of a 
questionnaire to measure asthma control. Eur Respir J. 1999  
Laidlaw T, Kidder M , Bhattacha ryya N, et al. Cysteinyl leukotriene overproduction in aspi[INVESTIGATOR_248] -
exacerbated respi[INVESTIGATOR_767932] -adherent leukocytes. Blood 2012 Apr 19;  
119(16):[ADDRESS_1053090] mite -induced allergic pulmonary inf lammation. Proc Natl Acad Sci 
[LOCATION_003] 2012 Jul 31;  109(31):[ADDRESS_1053091] 
15; 110(42):[ZIP_CODE] -92. 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053092] of aspi[INVESTIGATOR_767933] E4 
concentrations in aspi[INVESTIGATOR_248] -sensitive asthma. Am.  J. Respir.  Crit Care Med. 1995 May;151(5):[ADDRESS_1053093] s: a meta -analysis of the literature. J. Allergy Clin. 
Immunol. 135: 676 –681.e1.  
Schumacher  W, Heran C . Inhibition and Reversal of U -46,619 -lnduced Myospastic  Responses in 
Anesthetized Rats by [INVESTIGATOR_45220] 34,451 and Other  Thromboxane Antagonists.  Internal Report 1990 Dec 
26. 
Schumacher  W, Steinbacher  T. Inhibition of Bronchospasm and Arterial Hypertension in Guinea 
Pi[INVESTIGATOR_767934] 34,451 and SQ 34,943. Internal Report 1990 
Dec 29.  
Sousa AR, Parikh A, Scadding G, Corrigan CJ,  et al. Leukotriene -receptor expression on nasal 
mucosal inflammatory cells in aspi[INVESTIGATOR_248] -sensitive rhinosinusitis. N.  Engl.  J. Med. 2002 Nov 
7;347(19):1493 -9. 
White A, Stevenson D. Aspi[INVESTIGATOR_248] -Exacerbated Respi[INVESTIGATOR_31753]: Update on pathogenesis and 
desensitization. Semi n Respir Crit Care Med 2012 Dec;  33:588 -94. 
  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053094]’s legally 
authorized representative signing an IRB/IEC -approved consent form.  Subjects who do not speak 
English must be presented with  a consent form written in a language that they understand.  A copy 
of the signed consent form must be given to the subject signing it.  The original must be kept in 
the Investigator’s files and made available to Sponsor  and representatives of the appropri ate 
regulatory authority upon request.  If, for any reason, subject risk is increased as the study 
progresses, a revised, IRB/IEC -approved consent form must be signed by [CONTACT_423].  Before the 
study begins, a sample of the consent form must be provided t o the Sponsor .  The appropriate 
regulatory authority may reject otherwise scientifically valid studies if proper informed consent 
has not been obtained from all subjects.  
16.1.[ADDRESS_1053095] include explanations of each of the following 20  elements:  
• That the trial involves research  
• The purpose of the trial  
• The trial treatment(s) and the probability for random assignment to each treatment  
• The trial procedures to be followed, including all invasive procedures  
• The subject’s responsibilities  
• Those aspects of the trial that are experimental  
• The reasonably foreseeable risks or inconveniences to the subject and, when applicable, to 
an embryo, fetus, or nursing infant  
• The reasonably expected benefits; and when there is no intended clinical benefit to the 
subject, the subject should be made aware of this  
• The alternative procedure(s) or course(s) of treatment that may be available to the subject, 
and their important potential benefits and risks  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 46 • The compensation and/or treatment available to the subject in the event of a trial -related 
injury  
• The anticipated prorated payment, if any, to the subject for participating in the trial  
• The anticipated expenses, if any, to the subject for participating in the trial  
• That the subject’s participation in the trial is voluntary and that the subject may refuse to 
participate or withdraw from the trial, at any time, without penalty or loss of benefits to 
which the subject is otherwise entitled  
• That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory authority(ies) will be 
granted direct access to the subject’s original medical records for verification of clinical 
trial procedures and/or data, without violating the confidentiality of the subject, to the 
extent permitted by [CONTACT_120938], by [CONTACT_2960] a written informed 
consent form, the subject or the subject’s legally acceptable representative is authorizing 
such access  
• That the records identifying the subject will be kept confidential and, to the extent 
permitted by [CONTACT_29695]/or regulations, will not be made publicly available; 
and if the results of the trial are published, the subject’s identity will remai n confidential  
• That the subject or the subject’s legally acceptable representative will be informed in a 
timely manner if information becomes available that may be relevant to the subject’s 
willingness to continue participation in the trial  
• The person(s) to contact [CONTACT_767963], and whom to contact [CONTACT_44751] a trial -related injury  
• The foreseeable circumstances and/or reasons under which the subject’s participation in 
the trial may be terminated  
• The expected duration of the subject’s participation in the trial  
• The approximate number of subjects involved in the trial  
Nothing in these regulations is intended to limit the authority of a physician to provide emergency 
medical care to the extent the physician is permitted to do so under applicable federal, state, or 
local laws.  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053096] such claims.  
The informed consent requirements in these regulations are not intended to preempt any applicable 
federal, state, or local laws that require additional information to be disclosed in order that 
informed consent be legally effective.  Some states require fu rther action on the Investigator’s part 
concerning subject consent.  
16.[ADDRESS_1053097] submitted the following 
documents to the Study Monitor:  
• Signed protocol  
• Signed Statement of Investigator or FDA Form 1572 (if required by [CONTACT_61462])  
• Document indicating IRB/IEC approval of the final protocol , the informed consent and/or 
assent and recruitment advertisement document s (to include name, address, and 
chairperson of the IRB/IEC)  
• Blank copy of the IRB/IEC -approved informed consent document  
• Signed Investigator’s Agreement and Letter of Confidentiality  
• Clinical Laboratory Certification and normal ranges for tests that are performed in the 
laboratory for study assessments    
• Curricula vitae for the Investigator and Sub-Investigator (s) (i.e. individuals who, as part of 
an investigative team, will assist the investigator and make a direct and significant contribution 
to the data. In general, if an individual is directly involved in the performance of procedures 
required by [CONTACT_760], and the collection of data, that person should be listed on the 1572).  
• Financial disclosure Form FDA 3454  (any study FDA relies on to establish that the product 
is effective or any study in which a single investigator makes a significant contribution to 
the demonstration of safety ). 
 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 48 16.3 Responsibilities and Obligations of Investigators and Sponsors  
16.3.1  Sponsor/Study Monitor  
The CPI [INVESTIGATOR_767935]:  
Conduct a pre -investigation Site Selection Visit and/or Study Initiation Visit to:  
• Establish the acceptability of the facility and record the visit in a written report 
(i.e., memorandum or form).  
• Discuss with the Investigator the proposed clinical trial and supply draft CRFs, the 
Investigator’s Brochure, and the draft protocol for review and approval.  
• Discuss with the Investigator the regulatory requirements with respect to informed consent, 
IRB/IEC approval of the trial, the protocol, protocol amendments, and changes to the 
informed consent document.  
• Discuss with the Investigator the timing of interim and final reports to the Study Monitor 
and obligation to supply the Study Monitor with copi[INVESTIGATOR_120882] -related documents 
(including IRB/IEC approval, IRB/IEC charter or equivalent, membership and 
qualifications, protocol amendments, informed consent documents, and consent changes), 
CRFs, CRF changes, and all pertinent correspondence to and from the IRB/IEC.  
Conduct periodic on-site visit(s) to:  
• Assure adherence to the protocol.  
• Review CRFs and hospi[INVESTIGATOR_767936].  
• Examine pharmacy or other IMP storage and dispensing records for documentation of 
quantity and date of receipt of investigational drug, dispensation and accountability data 
for product administration to each subject, loss of materials, contamination, and unused 
supplies.  
• Record and report (summarize) observations on the progress of the trial and continued 
acceptability of the facilities, and prepare an on -site visit report.  
• Review Investigator files for required documents, (e.g., protocols; protocol amendments; 
Investigator’s Brochure; Study Procedures Manual; IRB/IEC approval of protocols, 
amendments, and informed consent documents; IRB/IEC charter and membership; and 
commun ications to and from the IRB/IEC and the Study Monitor.  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053098]/Independent Ethics Committee  
The Investigator must assure the Study Monitor in writing that the Institutional Review 
Board/Independent Ethics Committee (IRB/IEC):  
• Meets FDA 21CFR 56 and/or  ICH regulations as defined in ICH E 63: Institutional Review 
Board/Independent Ethics Committee  (as applicable) . 
• Has the authority delegated by [CONTACT_767964]/IEC by -laws, 
operation guidelines, or charter to approve or disapprove clinical trials and protocols, 
including informed consent and other documents (e.g., protocol amendments and 
information to be supplied to subjects concerning informed consent).  
• Complies with proper personnel make -up of the Board.  
• Convenes meetings using acceptable rules of order for making decisions, recording such 
decisions, and implementing them.  
• Maintains files that contain (a) documentation of its decisions, such as are found in 
IRB/IEC minutes and correspondence, (b) written guidelines or by -laws governing 
IRB/IEC functions, (c) protocol, (d) protocol amendments, (e) approved informed consent 
document and information to be supplied to the subject, and (f)  correspondence between 
the IRB/IEC and Investigator (e.g., consent changes, protocol amendments).  
Informed Consent of Human Subjects  
The Investigator must assure the Study Monitor in writing that the informed consent document for 
a subject:  
• Meets FDA 21CFR part 50 and/or  ICH regulations as defined in ICH E6 4.8: Informed 
Consent of Trial Subjects  (as applicable) . 
• Has been approved by [CONTACT_1201]/IEC, including (when required) information to be given to 
the subject regarding the trial in which he is enrolled.  
• Includes the basic elements and any additional elements of informed consent that are 
appropriate.  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 50 • Has been signed by [CONTACT_507651], and a copy has been 
given to the subject.  
• May be provided to the subject in the "short form" informed consent document with written 
information as an alternative.  
Storage and Dispensing of Product Supplies  
The Investigator (or Pharmacist) must assure the Study Monitor in writing that:  
• Adequate and accurate written records show receipt and disposition of all product supplies, 
including dates, serial or lot numbers, quantities received, and each quantity dispensed, 
administered, or used, with identification of each subject.  
• Purpose and reasons are given in written records for product disposal (e.g., the amount 
contaminated, broken, or lost) and the quantity that was returned to the Sponsor . 
Case Report Forms  
The Investigator must assure the Study Monitor in writing that:  
• The completed CRF accurately reflects the hospi[INVESTIGATOR_767937].  
• The CRFs and hospi[INVESTIGATOR_767938] -site 
visits.  
Files and Records  
The Investigator must assure the quality, integrity, and content of his files, which will be subject 
to audit by [CONTACT_767965].  The files must 
contain, as minimum:  
• Correspondence to and from the IRB/IEC and to and from the Clinical Monitor.  
• Documents including the following:  
o IRB/IEC -approved protocols.  
o IRB/IEC -approved protocol amendments.  
o IRB/IEC -approved informed consent /assent  document s and information to be supplied 
to the subject.  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 51 o IRB/IEC -approved recruitment advertisement(s)  
o IRB/IEC charter, membership, and qualifications of each member.  
• Clinical supplies records including the following:  
o Receipt, date and quantity, and batch or lot number.  
o Disposition dates and quantity administered to each subject.  
o Inventory records.  
Documents and records must be retained by [CONTACT_737] f or a period of two years following 
the date a marketing application is approved for the product for the indication for which it is being 
investigated,  OR If no application is to be filed or if the application is not approved for such 
indication, until two years after the investigation is discontinued and the appropriate regulatory 
authority is notified . 
16.[ADDRESS_1053099] ( SNOT -22) 
Below you will find a list of symptoms and social/emotional consequences of your rhinosinusitis. 
We would like to know more about these problems and would appreciate you answering the 
following questions to the best of your ability.  There are no right or wrong answers, and only you 
can provide us with this information. Please rate your problems as they have been over the past 
two weeks. Thank you for your participation.  Do not hesitate to ask for assistance if necessary.  
  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 52  
 
1. Considering  how severe  the problem  
is when  you experience  it and how 
often  it happens,  please  rate each item 
below  on how "bad"  it is by [CONTACT_767966] : →  
No Problem   
Very  Mild  Problem   
Mild  or slight  Problem   
Moderate  Problem   
Severe  Problem   
Problem  as bad as it can be   
[ADDRESS_1053100]  Important  Items  
 
1. Need  to blow  nose   
0  
1  
2  
3  
4  
5   
 
 
2. Nasal  Blockage   
0  
1  
2  
3  
4  
5  
 
 
3. Snee zing  
0  
1  
2  
3  
4  
5  
 
 
4. Runny  nose   
0  
1  
2  
3  
4  
5  
 
 
5. Cough   
0  
1  
2  
3  
4  
5  
 
 
6. Post-nasal  discharge   
0  
1  
2  
3  
4  
5  
 
 
7. Thick  nasal  discharge   
0  
1  
2  
3  
4  
5  
 
 
8. Ear fullness   
0  
1  
2  
3  
4  
5  
 
 
9. Dizziness   
0  
1  
2  
3  
4  
5  
 
 
10. Ear pain   
0  
1  
2  
3  
4  
5  
 
 
11. Facial  pain/pressure   
0  
1  
2  
3  
4  
5  
 
 
12.  Decreased  Sense  of Smell/Taste   
0  
1  
2  
3  
4  
5  
 
 
13. Difficulty  falling  asleep   
0  
1  
2  
3  
4  
5  
 
 
14. Wake  up at night   
0  
1  
2  
3  
4  
5  
 
 
15. Lack  of a good  night’s  sleep   
0  
1  
2  
3  
4  
5  
 
 
16. Wake  up tired   
0  
1  
2  
3  
4  
5  
 
 
17. Fatigue   
0  
1  
2  
3  
4  
5  
 
 
18. Reduced  productivity   
0  
1  
2  
3  
4  
5  
 
 
19. Reduced  concentration   
0  
1  
2  
3  
4  
5  
 
 
20. Frustrated/restless/irritable   
0  
1  
2  
3  
4  
5  
 
 
21. Sad  
0  
1  
2  
3  
4  
5  
 
 
22. Embarrassed   
0  
1  
2  
3  
4  
5  
 
2. Please  mark the most important  items affecting  your health  (maximum of 5 items)_________  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053101]. Louis, MO 
SNOT -22 Developed from  modification of SNOT -20 by  [CONTACT_767967].  
16.5 PNIFR Methodology  
Per Celikel 2013 : 
Traditional NIFR measurements can yield highly variable results. However, assessment of the rate 
of peak nasal inspi[INVESTIGATOR_10229] (PNIF) has recently been shown to be a n inexpensive, simple and 
fast method with  good reproducibility . 
The PNIF meter is simply an inverted mini -Wright flow meter attached to an airtight face mask. 
The PNIF is then measured using a Youlten meter  (or similar)  in liters per minute.  
All subject s should be instructed on how to use the Youlten meter properly . All subject s should be 
seated during testing  and encouraged to inhale as hard and fast as they can through the mask whi le 
keepi[INVESTIGATOR_767939] a ful l expi[INVESTIGATOR_1516]. Two individual NIFR 
measurements  will be taken at all study time points .  The two measurements within 5% of each 
will be recorded.  If the measurements are not within 5% of each other, a third measurement will 
be made  and recorded .   
  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 54 16.6 Total Nasal Symptom Score (TNSS)  
Please answer all the questions to the best of your ability twice daily, once in the morning after 
waking up and a second time before bedtime.  
                              0 = NONE     1 = MILD    2 = MODERATE    3 = SEVERE     
Date:  Date:  Date:  Date:  
 
AM PM AM PM AM PM AM PM 
Please rate how your nasal congestion  
has been over the past 12 hours:                  
Please rate how your runny nose  has 
been over the past 12 hours:                  
Please rate how your nasal itching  
has been over the past [ADDRESS_1053102] 12 hours:                  
Please rate how difficult has it been 
with nasal symptoms to sleep  or go 
about your day's activities :                 
 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 55 16.7 Asthma  Control  Questionnaire  –7 (ACQ -7) 
Please answer questions [ADDRESS_1053103] week, how often were you woken by [CONTACT_767968]?  
[ADDRESS_1053104] week, how bad are your asthma symptoms when you wake 
up in the morning?  
[ADDRESS_1053105] week, how limited were you in your activities because of your 
asthma?  
[ADDRESS_1053106] week, how much shortness of breath did you experience 
because of your asthma?  
0 None  
1 A very little  
2 A little  
3 A moderate amount  
4 Quite a lot  
5 A great deal  
6 A very great deal  
 
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment [ADDRESS_1053107] week, how much time did you wheeze?  
[ADDRESS_1053108] week, how many puffs/inhalations of short -acting 
bronchodilator (eg. Ventolin) have you used each day?  
0 None  
1 1-2 puffs/inhalations most days  
2 3-4 puffs/inhalations most days  
3 5-8 puffs/inhalations most days  
4 9-12 puffs/inhalations most days  
5 13-16 puffs/inhalations most days  
6 More than 16 puffs/inhalations most days  
 
7. (To be completed by [CONTACT_3655])  
FEV , % predicted:  
Points   
0 >95% predicted  
1 90-95% predicted  
2 80-89% predicted  
3 70-79% predicted  
4 60-69 predicted  
5 50-59% predicted  
6 <50% predicted  
Points assigned = ____________  
Scoring: Sum points from all questions 1 -7. Divide this sum by 7.  
If question 7 is not available, divide by 6.  
ACQ score = ___________  
Juniper 1999  
IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 57 16.8 Adult Equipotent Daily Doses of Inhaled Glucocorticosteroids  
     Bachert 2016  
 
 
 
 
 
 
 
 
 
 
 
 
 

IND 132982  [IP_ADDRESS] Clinical Study Protocol  
Cumberland Pharmaceuticals Inc.                                                                                                 Ifetroban Capsules  
 
CPI-IFE-006; Amendment 01   Page 58 16.9 Self-assessment of Treatment (Optional)  
We would like to better understand your opi[INVESTIGATOR_767940].  
Please, answer the following question. Thank you for your cooperation.  
Could you tell us about your opi[INVESTIGATOR_767941]? What 
did you like or dislike about the treatment?  
 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________ ________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
____________________________________________ __________________________________
______________________________________________________________________________
______________________________________________________________________________
__________________________________________________________________ ____________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________  
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________ ________________________________________________________
______________________________________________________________________________
______________________________________________________________________________  